Anti-P Glycoprotein antibody [UIC2] (FITC) (ab66250)
Overview
- Product nameAnti-P Glycoprotein antibody [UIC2] (FITC)See all P Glycoprotein primary antibodies ...
- DescriptionMouse monoclonal [UIC2] to P Glycoprotein (FITC)
- ConjugationFITC
- Specificityab66250 specifically recognises an extracellular conformational epitope of P Glycoprotein.
- Tested applicationsFlow Cyt more details
- Species reactivityReacts with: Human
Predicted to work with: Non Human PrimatesDoes not react with
Mouse, Rat - Immunogen
Mouse Balb/c 3T3 fibroblasts transfected with human P Glycoprotein cDNA
- General notesThis product is photosensitive and should be protected from light.
Clone UIC2 does not crossreact with mitochondrial pyruvate carboxylase.
Properties
- FormLiquid
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.09% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4 -
Concentration information loading... - PurityProtein G purified
- Purification notesPurified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant.
- Primary antibody notes Clone UIC2 does not crossreact with mitochondrial pyruvate carboxylase.
- Clonality Monoclonal
- Clone numberUIC2
- IsotypeIgG2a
- Research Areas
Applications
Our Abpromise guarantee covers the use of ab66250 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| Flow Cyt | Flow Cyt: Use 10µl for 106 cells. (in 100µl). Clone UIC2 can also be used in a shift assay to selectively demonstrate the expression and functional activity of P Glycoprotein in a target cell. |
Target
- FunctionEnergy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Tissue specificityExpressed in liver, kidney, small intestine and brain.
- Involvement in diseaseGenetic variations in ABCB1 are associated with susceptibility to inflammatory bowel disease type 13 (IBD13) [MIM:612244]. Inflammatory bowel disease is characterized by a chronic relapsing intestinal inflammation. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may involve any part of the gastrointestinal tract, but most frequently the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Crohn disease and ulcerative colitis are commonly classified as autoimmune diseases.
- Sequence similaritiesBelongs to the ABC transporter superfamily. ABCB family. Multidrug resistance exporter (TC 3.A.1.201) subfamily.
Contains 2 ABC transmembrane type-1 domains.
Contains 2 ABC transporter domains. - Cellular localizationMembrane.
-
Database links
- Entrez Gene: 5243 Human
- Omim: 171050 Human
- SwissProt: P08183 Human
- Unigene: 489033 Human
Target information above from: UniProt accession
P08183
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010)
.
-
Alternative names
- ABC20 antibodyABCB1 antibodyATP binding cassette sub family B MDR/TAP member 1 antibody
- ATP binding cassette, sub family B (MDR/TAP), member 1 antibodyATP-binding cassette sub-family B member 1 antibodyCD243 antibodyCD243 antigen antibodyCLCS antibodyColchicin sensitivity antibodyDoxorubicin resistance antibodyGP170 antibodyMDR 1 antibodyMDR1 antibodyMDR1_HUMAN antibodyMultidrug resistance 1 antibodyMultidrug resistance protein 1 antibodyP glycoprotein 1 antibodyP gp antibodyP-glycoprotein 1 antibodyPGY1 antibody
see all
References for Anti-P Glycoprotein antibody [UIC2] (FITC) (ab66250)
This product has been referenced in:
- Boyerinas B et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 130:1787-97 (2012). Read more (PubMed: 21618519) »
- Yan F et al. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 9:287-95 (2010). Flow Cyt ; Human . Read more (PubMed: 20525557) »
